Cargando...

Ardilan Inyectable IV - Enalaprilato 2,5 mg - Frasco Ampolla x 2 ml.

data:image/png;base64,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

    Clase Terapeutica

  • CARDIOLOGÍA

    • Acciones Terapeuticas

  • PARA EL TRATAMIENTO DE LA HIPERTENSION ARTERIAL EN TODOS SUS GRADOS

    • Principios Activos

  • ENALAPRILATO

    • Concentración

  • 2,5 MG

    • Presentación

  • SOLUCION INYECTABLE

Mas Info

Está indicado para el tratamiento de la hipertensión cuando la terapia oral no es práctica.

También te puede interesar

Ardilan 10 mg - Enalapril 10 mg - Caja de 30 Comprimidos Ranurados.

PARA EL TRATAMIENTO DE LA HIPERTENSION ARTERIAL EN TODOS SUS GRADOS, INSUFICIENCIA CARDIACA CONGESTIVA

ENALAPRIL

Ardilan 20 mg - Enalapril 20 mg - Caja de 30 Comprimidos Ranurados.

PARA EL TRATAMIENTO DE LA HIPERTENSION ARTERIAL EN TODOS SUS GRADOS, INSUFICIENCIA CARDIACA CONGESTIVA

ENALAPRIL MALEATO

Ardilan D - Cont. 30 Comprimidos

PARA EL TRATAMIENTO DE LA HIPERTENSION ARTERIAL EN TODOS SUS GRADOS, INSUFICIENCIA CARDÍACA CONGESTIVA CON TERAPIA COMBINADA

ENALAPRIL, HIDROCLOROTIAZIDA



CALIDAD

Estamos comprometidos con la salud de las personas.

SOSTENIBILIDAD

Producción comprometida con el futuro.

PROFESIONALISMO

Equipo profesional especializado.